MindMaze Therapeutics banks first CHF 4M of CHF 8M Neuro.io financing
What's the deal? MindMaze Therapeutics (SIX: MMTX) has completed the first tranche of its CHF 8 million strategic equity financing with Neuro.io Group SADealroom has a profile for this one. Try Dealroom →, receiving gross proceeds of CHF 4 million. The Geneva-based neurotherapeutics company disclosed the update alongside the completion of an organizational simplification effort.
How it works: Under the first tranche, MindMaze transferred 4,970,000 treasury shares to Neuro.ioDealroom has a profile for this one. Try Dealroom →. Newly issued CHF 2,850,900 in mandatory convertible loan notes were converted into 12,395,217 ordinary shares.
Why now? MindMaze, formerly NeuroXDealroom has a profile for this one. Try Dealroom →, is refocusing on its core neurology business. It has disposed of substantially all remaining non-neurology legacy operations acquired through its combination with Relief TherapeuticsDealroom has a profile for this one. Try Dealroom →, aiming to cut costs and support US commercial priorities.
What's the endgame? The company builds precision neurotherapeutics that combine software, sensors, and AI-driven analytics to treat stroke, Parkinson's disease, and other neurological disorders. Its FDA-listed and CE-marked products span hospital, outpatient, and home care.
What could go wrong? The parties revised the schedule for the second CHF 4 million tranche, now due in two installments across September and November 2026. The company warned there is "no assurance as to its timing or completion" and said it is pursuing additional financing to support liquidity.
The signal: At roughly $9.9 million, the raise sits in the smaller tier of financings — a modest, staged capital injection rather than a transformative one. It reads as a company trimming to its core and buying runway while it hunts for further funding.
Read more: Marktpuls
Image credit: Generated with Gemini
